For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
